Navegando por Assunto "Primaquina"

Agora exibindo 1 - 9 de 9

Acesso aberto (Open Access)
Adesão ao tratamento da malária vivax em crianças
(Universidade Federal do Pará, 2016-04-01) SANTOS, José Alberto Gomes dos; ANDRADE, Marcieni Ataíde de; http://lattes.cnpq.br/8514584872100128
Malaria is an infectious disease endemic in 104 countries and vivax malaria accept responsibility for 25 to 40% of the global burden of disease worldwide. The South America has high transmission rates shown by the annual parasite incidence (API) greater than 1% of the population. In recent years it has been observed in Brazil the prevalence of infection with P. vivax. The treatment protocol isased on the combination of chloroquine and primaquine, however, treatment failures have been reported worldwide including in Brazil with adherence as one of the causes. Several factors can interfere in the adherence between them: education, sex, absence of signs and symptoms and socioeconomic profile. This study evaluated the adherence to malaria treatment from determining the profile demographic partner of children with vivax malaria in Anajás and determined the plasma concentrations of chloroquine and primaquine of the study patients. For the profile of the participants was used questionnaire was complete source of information. To measure adherence to treatment was used indirect test Morisky-Green assessing the patient's attitude towards treatment. The plasma concentration of primaquine and its metabolite was made by collecting paper filter venous blood on day D1 and D7 and determined HPLC. The profile of patients showed that most of the children were male, with the primary caregiver mother, education and income were considered low, despite the distribution the use of mosquito nets it is irregular, 92.4% of households have no sewage system, and 33.3% use water from the river for consumption .The indirect test Morisky- Green classified 42 children as adherent and 08 as no adherent The plasma concentration of PQ in D7 adherent and no adherent were related and showed no significant difference, since the CPQ concentrations in D7 Adherent showed statistically significant result, with higher values in adherent patients.
Acesso aberto (Open Access)
Alterações clínicolaboratoriais em pacientes com malária por Plasmodium vivax e deficiência de glicose-6-fosfato desidrogenase tratados com 0,50mg/kg/dia de primaquina
(2004-06) SILVA, Mônica Cristina de Moraes; SANTOS, Eliane Barbosa; COSTA, Elenild de Góes; SILVA FILHO, Manoel Gomes da; GUERREIRO, João Farias; PÓVOA, Marinete Marins
The adverse effects of primaquine (0.50mg/kg/day) were investigated in eleven patients with vivax malaria (three patients with glucose-6-phosphate dehydrogenase deficiency). Clinical and laboratorial alterations indicated acute hemolysis in only the enzymopenic patients and treatment was interrupted. Our results suggest that screening for G6PD deficiency should be carried out in patients with vivax malaria infection in order to avoid complications due to primaquine.
Acesso aberto (Open Access)
Avaliação da adesão ao tratamento preconizado para malária: determinação da primaquina em pacientes diagnosticados com Plasmodium vivax
(Universidade Federal do Pará, 2016-03-31) GONÇALVES FILHO, Wilson Vieira; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098; ANDRADE, Marcieni Ataíde de; http://lattes.cnpq.br/8514584872100128
Malaria is a disease that threatens 50% of the world population living in endemic areas such as Africa, Asia and Latin America. Concerning malaria caused by Plasmodium vivax in Brazil, which treatment is based on primaquine and chloroquine, it is a major public health issue that hinders the development of the Amazon region and adherence to drug therapy is one of the main factors that influence the effectiveness of the drug. This study uses indirect methods assess treatment adherence, correlating it with plasma concentrations of primaquine and carboxyprimaquine. Thus, a cross-sectional observational controlled study was conducted with 27 patients in Anajás, Pará before (D0), during (D1) and after (D7) treatment using the antimalarials, followed by the assessment of the patients with questions based on Morisky-Green test at the end of the treatment. Higher prevalence of vivax malaria was observed in males (70.4%) and age group of 20-39 years (55.56%), Morisky-Green test indicated adherence of 75%, 15 out of 20 patients, with hit rates of 80%, 65%, 70% and 65% to the questions. Mean-value of primaquine concentration on D1 was 134.8 ng/mL, and 131.9 ng/mL on D7, values for carboxyprimaquine are 408 ng/ml and 529.4 ng/mL respectively. It is possible to observe a statistically significant difference in the carboxyprimaquine values between D1 and D7 in the acceding group defined by the Morisky-Green tests, showing that carboxyprimaquine accumulates in the body; therefore being more suitable for assessing adherence to treatment. Therefore, it is important to point out these concentrations of primaquine and carboxyprimaquine consist as the first determination study of drugs and metabolites found for the short-course treatment suggested by the Ministry of Health for vivax malaria in the Amazon region, supporting the studies of adherence surveys regarding antimalarials.
Acesso aberto (Open Access)
Avaliação da resposta aos esquemas de tratamento reduzidos para malária vivax
(Universidade Federal do Pará, 2001-08) ABDON, Nagib Ponteira; PINTO, Ana Yecê das Neves; SILVA, Rita do Socorro Uchôa da; SOUZA, José Maria de
Relapses may occur with long standard treatment of vivax malaria, and these are caused by incomplete patient’s compliance. The use of reduced schedules may further better patient compliance, while maintaining the same efficacy, tolerance and minimal adverse reactions. The objective of this study was to test two schedules with reduced doses of chloroquine for vivax malaria and comparing these with the classical schedule. The authors studied 120 outpatients, with vivax malaria, aged over 12 years, submitted to three therapeutic schemes: scheme I: chloroquine phosphate (150mg) in a dose of 25mg/kg/day for three days (10mg/kg/ day in the first day, 7.5mg/kg/day in the second and third day), plus primaquine (15mg) in a dose of 0.25mg/kg/day for fourteen days; scheme II: chloroquine, in a single dose of 10mg/kg, plus primaquine in a dose of 0.5mg/kg/day for seven days; scheme III: chloroquine, 10mg/kg in a single dose plus primaquine in a dose 0.5mg/kg/ day for five days. The clinical response to all three therapeutic schemes was satisfactory. The disappearance of malarial symptoms occurred after a maximum 96 hours of treatment, while the assexual parasitaemia clearance occurred within 72 hours, in all therapeutic schemes.
Acesso aberto (Open Access)
Avaliação da terapêutica da malária por Plasmodium vivax: perfil cinético da cloroquina e primaquina
(Universidade Federal do Pará, 2011) TEIXEIRA, José Ribamar Mesquita; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098; SOUZA, José Maria de; http://lattes.cnpq.br/6459204248879587
Today search - new strategies for improving the treatment and control of malaria. The monitoring of plasma concentrations of drugs is an important tool that aims to provide more knowledge on the kinetics of several antimalarial drugs, aiming to achieve rapid therapeutic effect with reduced risk of toxicity. Thus, this study aimed to evaluate the therapeutic response to chloroquine and primaquine for vivax malaria patients, the plasma concentrations correlate with parasitemia, epidemiological data and evaluation of liver and kidney function, aiming at the optimization of various therapeutic regimens employed, evaluating if the responses are due to ineffective treatment of Plasmodium resistance to chloroquine or the presence of sub-therapeutic concentrations of drugs. Thus, we evaluated 40 patients with vivax malaria in the Program in Clinical Trials of Malaria Institute Evandro Chagas (Belém, Pará) in the period 2008 to 2010. Hemogram and other biochemical parameters were performed. The research of plasmodia in blood smear was performed and the parasitemia averaged 7187.5 ± 6732.7 parasitos/mm3. The prevalence of males with 67.5% of cases. The locations of malaria infection ranged from 14 municipalities in the state of Pará, most of which originates in the city of Anajás. For 42.5% of patients it was the first episode of the disease and 57.5% of applicants. In the evaluation of anemia by hemoglobin, there - if the levels below reference values in 60% of patients and hematological and biochemical parameters showed that the mean values of hematocrit and red blood cells showed highly significant difference between subgroups of patients and non-anemic anemic. The determination of chloroquine and primaquine in patients on D0, D2, D7, D14 and D30 were performed. The mean values of 0, 1102.1, 546.7, 185.8 and 98.6 ng / ml for chloroquine and 0, 210.2, 345.0, 91.7 and 0 ng/ml for primaquine.
Acesso aberto (Open Access)
Concentrações plasmáticas de primaquina e metemoglobinemia em pacientes com malária por Plasmodium vivax
(Universidade Federal do Pará, 2010) FERREIRA, Michelli Erica Souza; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098
The vivax malaria is a disease that effects around 40% of the world, to treat it, chloroquine (150 mg) and primaquine (15 mg). This is an 8-aminoquinoline with tissue schizonticide action. Among the adverse effects enhance the capacity to hemoglobin oxidation, dose-dependent, which is exacerbated in individuals with glucose-6-phosphate dehydrogenase deficiency. When considering the lack of studies concerning the methemoglobin levels and its correlation with primaquine concentrations plasma in patients with vivax malaria, is justified this study using as tools to monitor the plasma primaquine concentrations and its correlation with methemoglobin levels. In this sense, it was followed up clinically and laboratory findings of 20 patients with vivax malaria before (D0) and after three (D3), seven (D7) and fourteen (D14) days starting the treatment, as well as validation of the method for primaquine determination by high performance liquid chromatography (HPLC). Methemoglobinemia was evaluated using the method of Hegesh et al. (1970) and glucose-6-phosphate dehydrogenase by colorimetric method of Brewer et al. (1962 ). The methodology validated was demonstrated efficient for primaquine determination, whose average levels at D3, D7 and D14 were 227 ± 106 ng / mL, 191 ± 97 ng / mL and 160 ± 128 ng/mL. In the analysis according to gender was not observed differences significant in the drug levels in several days of study. The average methemoglobin levels in D0, D3, D7 and D14 were 1.15 ± 0.9%, 4.1 ± 2%, 5.7 ± 2% and 3 ± 1.4%, respectively. There was an increase in the methemoglobin level after drug administration, without difference by gender. There was not significant correlation between the methemoglobin levels and primaquine concentrations plasma in both sexes. The coefficients of Pearson correlation for males and females were 0.8296 and 0.8137, respectively. We observed impaired expression of the enzyme glucose-6-phosphate dehydrogenase in six male patients without differences between the methemoglobin levels and primaquine concentrations plasma, compared with patients with expression normal of the enzyme.
Acesso aberto (Open Access)
Efeitos do uso crônico do difosfato de primaquina sobre a prenhez da rata
(Universidade Federal do Pará, 1998-10) AZEVEDO, Eliel Nina de; SANTOS, Alessandra Silva; MENDES, Eliane Terezinha Rocha; SIMÕES, Manuel de Jesus; KULAY JÚNIOR, Luiz
Purpose: to evaluate the chronic action of primaquine diphosphate on the pregnancy of female albino rats. Methods: sixty pregnant female rats, separated into six groups, were used. Group I received daily, by gavage, 1 ml of distilled water from day zero to the 20th day of pregnancy (control group). The female rats of the other groups also received daily, by gavage, during the same period of time the volume of 1 ml containing gradually concentrated primaquine diphosphate solution: 0.25 mg/kg, group II; 0.50 mg/kg, group III; 0.75 mg/kg, group IV; 1.5 mg/kg, group V and 3.0 mg/kg, group VI. The maternal weights were considered on day zero and on the 7th, 14th and 20th days of pregnancy, when the matrices were sacrificed. Results: the results showed that primaquine diphosphate, in the used doses, did not interfere with none of the following variables: maternal weight, newborn weight, medium individual weight of fetuses, weight of the group of placentas and medium individual weight of the placentas, implantation number, number of placentas and number of fetuses, when compared with the control group. Also there was no case of reabsorption, malformation, maternal mortality or intrauterine death, in any of the studied groups. Conclusion: in the conditions of the study there were no contraindications for the continuous use of primaquine diphosphate during the pregnancy of the female rat.
Acesso aberto (Open Access)
Marcadores de estresse oxidativo e concentrações de primaquina e carboxiprimaquina em pacientes com malária por Plasmodium vivax
(Universidade Federal do Pará, 2014-11-06) RODRIGUES, Luiz Carlos de Souza; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098
The changes in redox cycle has been associated with the physiopathology of severity of malaria in experimental models and in humans. However, a few studies evaluated the changes in redox equilibrium of patients with no severe malaria by P.vivax, which comprise the majority of the cases of disease. The variations of oxidative damage and the respective antioxidant response of human host were not compared before, during and after chemotherapy. Also, the mechanisms responsible by the generation of free radical in each phase that is, the heme degradation, respiratory burst of macrophages or antimalarials uses, were not determined. The objective of this study was to estimate the levels of biomarkers of oxidative damage and the respective antioxidant response, as well as primaquine and carboxyprimaquine whole blood levels in malaria by P. vivax. Therefore, were enrolled 38 patients with slide confirmed infection by P. vivax followed by 28 days. Serial blood samples were collected on pre-doses samples (D0) and on D2, D7 and D14. The oxidative damage and the antioxidant defense were estimated by the spectrophotometric measures of thiobarbituric acid reatives substances and methemoglobinemia, and by total antioxidant capacity and reduced glutathione, respectively. The control group consisted of 19 healthy volunteers matched for age and gender ratio. Primaquine and its major metabolite were determined by high performance liquid chromatography. The results revealed that the disease occurred in male patients of working age. Haematological parameters remained constant during the study. Biochemical evaluation showed a significant decrease in HDL-cholesterol levels during the study. Methemoglobinemia was associated with antimalarials uses, because the levels were similar to control group and increased significantly during the treatment. The levels of thiobarbituric acid reatives substances were associated with plasmodium and probably respiratory burst of macrophages, because they were higher than control group on D0, and no significant changes were observed after antimalarials usage. Total antioxidant capacity and oxidative stress levels were similar during the study as well as in the control group. The levels of reduced glutathione decreased significantly during the study and doesn’t be associated with both parasitaemia. Primaquine does not show a significant accumulation, and the concentrations of parent drug and its carboxyl metabolite were not associated with methemoglobinemia and thiobarbituric acid reatives substances levels.
Acesso aberto (Open Access)
Metemoglobinemia em pacientes com malária por Plasmodium vivax em uso oral de primaquina
(2011-02) FERREIRA, Michelli Erica Souza; GOMES, Margarete do Socorro Mendonça; VIEIRA, José Luiz Fernandes
Primaquine can produce adverse reactions as toxicity to blood when used in the treatment of vivax malaria. This work aimed to determine methemoglobinemia in patients with vivax malaria receiving oral therapy with primaquine. Methods: Spectrophotometric quantification of methemoglobinemia and qualitative assay for glucose-6-phosphate dehydrogenase. Results: Methemoglobinemia ranged from 2.85 to 5.45% in male patients and 3.77 to 7.34% in female patients. Conclusions: A statistically significant increase in methemoglobinemia was observed following oral therapy with primaquine, with no clinical manifestations, and independent of sex and the qualitative expression of glucose-6-phosphate dehydrogenase.